AFFECTED TESTS:

- **FETAL FIBRONECTIN [LAB287]**

EXPLANATION:

FETAL FIBRONECTIN [LAB287] will be discontinued due to its limited value in assessing the risk of preterm delivery in both symptomatic and asymptomatic pregnant women. Research studies showed that a positive fetal fibronectin result did not substantially change the pre-test probability of preterm delivery, and that a negative result did not substantially reduce the post-test probability. The test volume at Ruby has significantly dropped, since multiple guidance documents recommended against routine use of fetal fibronectin to stratify risk for pre-term delivery.

AMNISURE [LAB304997] will remain orderable for the detection of amniotic fluid in vaginal secretions of pregnant patients who report signs, symptoms or complaints suggestive of rupture of membranes.

REFERENCES:
1. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 171: Management of Preterm Labor. Obstet Gynecol. 2016 Oct;128(4):e155-64.
2. Farnsworth C, Schuler EE, Woodworth A, et al. AACC Guidance Document on Laboratory Testing for the Assessment of Preterm Delivery. J Appl Lab Med. 2021 Jul 7;6(4):1032-1044.
3. NICE Guideline on Preterm labour and birth. (last updated Jun 10, 2022) https://www.nice.org.uk/guidance/ng25/chapter/Recommendations#diagnosing-preterm-labour-for-women-with-intact-membranes Accessed on May 24, 2023

QUESTIONS ABOUT THIS TESTING
Meranda Mancino, MT (ASCP), Technical Specialist, Auto Chemistry at 304-598-3214
meranda.mancino@wvumedicine.org
Jianbo Yang, PhD, Assistant Director – Chemistry & Clinical Mass Spectrometry Laboratories, 304-598-6393, (jianbo.yang@hsc.wvu.edu);
Danyel Tacker, PhD (DABCC), Director Clinical Chemistry at 304-598-4243
dtacker@hsc.wvu.edu

QUESTIONS
Contact WVUH Laboratories 304-598-4241 or
MLS Representatives 304-285-7201

ADDITIONAL INORMATION AVAILABLE ONLINE: WVUH Test Catalog